Isolation of bacteriophages to multi-drug resistant Enterococci obtained from diabetic foot: A novel antimicrobial agent waiting in the shelf

Indian Journal of Pathology and Microbiology

Volumn 54, Issue 1, 2011, Pages 90-95

  Vinodkumar, C S ^a   Srinivasa, H ^b   Basavarajappa, K G ^a   Geethalakshmi, S ^c   Bandekar, Nitin ^a  

^a S S Institute of Medical Sciences and Research Centre   (India)

^b ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^c MADRAS MEDICAL COLLEGE   (India)

Author keywords

Bacteriophage; diabetic foot; Enterococcus faecalis; high level aminoglycoside resistance

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CEFOTAXIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; ERYTHROMYCIN; GENTAMICIN; INSULIN; LINEZOLID; OFLOXACIN; ORAL ANTIDIABETIC AGENT; PENICILLIN G; SH 56; STREPTOMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ADULT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIOPHAGE; BACTERIOPHAGE SH 56; BACTERIUM ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC PATIENT; DISEASE SEVERITY; DISK DIFFUSION; ENTEROCOCCAL INFECTION; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FEMALE; HOSPITAL ADMISSION; HUMAN; MALE; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; NONHUMAN; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; BACTERIOPHAGES; BIOLOGICAL THERAPY; DIABETIC FOOT; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES;

EID: 79952915868     PISSN: 03774929     EISSN: 09745130     Source Type: Journal    
DOI: 10.4103/0377-4929.77333     Document Type: Article

References (33)

1. Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev 1990;3:46-65. (Pubitemid 20078774)
2. Jesudason MV, Pratima VL, Pandian R, Abigail S. Characterization of penicillin resistant Enterococci. Indian J Med Microbiol 1998;16:8-16.
3. Frykberg RG. Diabetic foot ulcers: Current concepts. J Foot Ankle Surg 1998;37:440-6. (Pubitemid 28481979)
4. Blazer K, Heidrich M. Diabetic gangrene of the foot. Chirurg 1999;70:831-44.
5. Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, et al. Diagnosis and Treatment of Diabetic Foot Infections. Clin Infect Dis 2004;39:885-910. (Pubitemid 39328144)
6. Shea KW. Antimicrobial therapy for diabetic foot infections. A practical approach. Postgrad Med 1999;106:85-6,89-94. (Pubitemid 29327712)
7. Patterson JE, Zervos M. High-level gentamicin resistance in Enterococcus: Microbiology, genetic basis and epidemiology. Rev Infect Dis 1990;12:644-51.
8. Moellering RC Jr. Emergence of Enterococcus as a significant pathogen. Clin Infec Dis 1992;14:1173-8.
9. Duckworth DH, Gulig PA. Bacteriophages: Potential treatment for bacterial infections. Biodrug 2002;16:57-62. (Pubitemid 34303968)
10. Alisky J, Iczkowski K, Rapoport A, Troitsky N. Bacteriophage shows promise as antimicrobial agents. J Infect 1998;36:5-15. (Pubitemid 128645619)
11. Facklam RR, Collins MD. Identification of Enterococcus species isolated from human infections by conventional test scheme. J Clin Microbiol 1989;24:731-4.
12. Bauer AW, Kirby WM, Sherris JC, Jurek M. Antibiotic susceptibility testing by a standardized disc method. Am J Clin Pathol 1966;45:493-6.
13. NCCLS. Performance Standards for antimicrobial susceptibility testing. 12th Informational Suppliment. NCCLS document M100-S12[ ISBN 1-56238-454-6]. USA: NCCLS; 2002.
14. Smith HW, Huggins MB. Successful treatment of experimental E. Coli infections in mice using phage; its superiority over antibiotics. J Gen Microbiol 1982;128:307-18. (Pubitemid 12159900)
15. Tartero C, Araujo R, Michel T, Jofre J. Culture and methods affecting decontaminating, enumeration of phage infecting Bacteriodes fragilis in sewage. Appl Environ Microbiol 1992;58:2670-3.
16. Sambrook JE, Maniatis TF. Molecular cloning; A laboratory manual. 2nd ed. Cold Spring Harbor. New York: Cold Spring Harbor Laboratory Press;1989.
17. Eaton MD, Stanhope BJ. Bacteriophage therapy. JAMA 1934;103:1769-76, 1847-53, 1934-9.
18. Shakar RG, Madhusudhan V, Palaniappan P. Evaluation of phage therapy to treat experimental infection in mice. Indian J Microbiol 1998;38:101-3. (Pubitemid 128439523)
19. Biswas B, Adhya S, Washart P, Paul B, Trostel AN, Powell B, et al. Bacteriophage therapy rescues mice bacteremia from a clinical isolates of Vancomycin resistant Enterococcus feacium. Infect Immun 2002;70:204-10. (Pubitemid 34028619)
20. Dubos RJ, Straus JH, Pierce C. The multiplication of bacteriophage invivo and its protective effect against an experimental infection with Shigella dysenteriae. J Exp Med 1943;20:191-68.
21. Bhat KG, Chitra P, Bhat M. High level aminoglycoside resistance in Enterococci isolated from hospitalized patients. Indian J Med Res 1997;105:198-9. (Pubitemid 27239086)
22. Desai PJ, Pandit D, Mathur M, Gogete A. Prevalence, identification and distribution of various species of enterococci isolated from clinical specimens with special reference to UTI in catheterized patients. Indian J Med Microbiol 2001;19:132-7.
23. Agarwal VA, Jain YI, Pathak AA. Concomitant high level resistance to penicillin and aminoglycosides in enterococci at Nagpur, Central India. Indian J Med Microbiol 1999;17:85-7.
24. Karmarkar MG, Gersham ES, Mehta PR. Enterococcal infections with special reference to phenotypic characterization and drug resistance. Indian J Med Res 2004;119:22-5 (Pubitemid 39004440)
25. Gordon S, Swenson J, Hill BC, Pigott NE, Facklam RR, Cooksey RC, et al. Antimicrobial susceptibility patterns of common and unusual species of Enteroccoci causing infections in United States. J Clin Microbiol 1992;30:2373-8.
26. Cetinkaya Y, Falk P, Mayhah CG. Vancomycin resistant Enterococcus. Clin Microbiol Rev 2000;13:686-707.
27. Schouten MA, Voss A, Hoogkamp-Korstanje; The Europeon VRE study group. Antiicrobial susceptibility patterns of Enterococci causing infections in Europe. Antimicrob Agents Chemother 1999;43:2542-6.
28. Barrow PA. Novel approaches to control of bacterial infections in animals. Acta Vet Hung 1997;45:317-29. (Pubitemid 127448173)
29. Bojovazova GG, Voroshilova NN, Bondarenko VM. The efficacy of Klebsiella bacteriophage in the therapy of experimental Klebsiella infection. J Microbiol Epidemiol Immunobiol 1991;4:5-8.
30. Soothill JS. Bacteriophage prevents destruction of skin grafts by Klebsiella sps. Burns 1994;20:209-11. (Pubitemid 24163010)
31. Vinod Kumar CS, Makari HK, Srinivasa H, Basavarajappa KG, Kalsurmath S. Bacteriophage therapy: A potential Use of Phages in Medical field. Res Rev BioSciences 2009;12:22-8.
32. Bush K. New beta lactamases in Gram-negative bacteria: Diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 2001;32:1085-9. (Pubitemid 32299644)
33. Logerfo FW, Coffman JD. Current concepts. Vascular and microvascular diseases of the foot in diabetes. N Engl J Med 1984;311:1615-9. (Pubitemid 15175203)